Literature DB >> 31194860

Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.

Nikki Higa1, Amy Pelz1, Donald Birch1, Ingrid A Beck1, Tatiana Sils1, Pearl Samson2, Mutsawashe Bwakura-Dangarembizi3, Carolyn Bolton-Moore4,5, Edmund Capparelli6, Ellen Chadwick7, Lisa M Frenkel1,8.   

Abstract

Among 66 antiretroviral-naive children aged <3 years with human immunodeficiency virus (HIV) or coinfected with HIV and tuberculosis and initiating efavirenz-based antiretroviral therapy (ART), non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance was detected before ART in 5 (7.6%). Virologic failure occurred in 2 of these children; they were last tested at 16 and 24 weeks of ART. Pre-ART NNRTI resistance was not associated with virologic failure.
© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV drug resistance; HIV-infected children; HIV/TB coinfection; NNRTI resistance; efavirenz

Year:  2020        PMID： 31194860      PMCID： PMC7192398          DOI： 10.1093/jpids/piz038

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  10 in total

1.  High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali.

Authors:  Claudia S Crowell; Almoustapha I Maiga; Mariam Sylla; Babafemi Taiwo; Niaboula Kone; Assaf P Oron; Robert L Murphy; Anne-Geneviève Marcelin; Ban Traore; Djeneba B Fofana; Gilles Peytavin; Ellen G Chadwick
Journal:  Pediatr Infect Dis J       Date:  2017-11       Impact factor: 2.129

2.  Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

Authors:  Louise Kuhn; Ashraf Coovadia; Renate Strehlau; Leigh Martens; Chih-Chi Hu; Tammy Meyers; Gayle Sherman; Gillian Hunt; Deborah Persaud; Lynn Morris; Wei-Yann Tsai; Elaine J Abrams
Journal:  Lancet Infect Dis       Date:  2012-03-16       Impact factor: 25.071

3.  CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Authors:  Carolyn Bolton Moore; Edmund V Capparelli; Pearl Samson; Mutsa Bwakura-Dangarembizi; Patrick Jean-Philippe; Carol Worrell; Barbara Heckman; Lynette Purdue; Stephen A Spector; Alex Benns; William Borkowsky; Amy Loftis; Elizabeth Hawkins; Carole Wallis; Ellen G Chadwick
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

Review 4.  Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  R S Boerma; K C E Sigaloff; A S Akanmu; S Inzaule; M Boele van Hensbroek; T F Rinke de Wit; J C Calis
Journal:  J Antimicrob Chemother       Date:  2016-12-20       Impact factor: 5.790

5.  Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.

Authors:  Ruth Kanthula; Theresa M Rossouw; Ute D Feucht; Gisela van Dyk; Ingrid A Beck; Rachel Silverman; Scott Olson; Christen Salyer; Sharon Cassol; Lisa M Frenkel
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

6.  Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.

Authors:  Ashraf Coovadia; Elaine J Abrams; Renate Strehlau; Stephanie Shiau; Francoise Pinillos; Leigh Martens; Faeezah Patel; Gillian Hunt; Wei-Yann Tsai; Louise Kuhn
Journal:  JAMA       Date:  2015-11-03       Impact factor: 56.272

Review 7.  A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Authors:  Michele W Tang; Phyllis J Kanki; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2012-03       Impact factor: 9.079

8.  High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.

Authors:  Ragna S Boerma; T Sonia Boender; Kim C E Sigaloff; Tobias F Rinke de Wit; Michael Boele van Hensbroek; Nicaise Ndembi; Titilope Adeyemo; Edamisan O Temiye; Akin Osibogun; Pascale Ondoa; Job C Calis; Alani Sulaimon Akanmu
Journal:  J Int AIDS Soc       Date:  2016-11-10       Impact factor: 5.396

9.  Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Authors:  Adriaan E Basson; Soo-Yon Rhee; Chris M Parry; Ziad El-Khatib; Salome Charalambous; Tulio De Oliveira; Deenan Pillay; Christopher Hoffmann; David Katzenstein; Robert W Shafer; Lynn Morris
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

10.  Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

Authors:  Janneke H van Dijk; Catherine G Sutcliffe; Francis Hamangaba; Christopher Bositis; Douglas C Watson; William J Moss
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240
  10 in total
  1 in total

Review 1.  Mitochondrial changes associated with viral infectious diseases in the paediatric population.

Authors:  Sonia Romero-Cordero; Antoni Noguera-Julian; Francesc Cardellach; Clàudia Fortuny; Constanza Morén
Journal:  Rev Med Virol       Date:  2021-03-31       Impact factor: 11.043
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.